Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition (PRESS RELEASE) CAMBRIDGE, 7-Jan-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, amyloid fibril deposits, amyloidosis, AstraZeneca, ATTR-CM, cardiomyopathies, Heart, heart failure, human monoclonal antibody, licence agreement, Marc Dunoyer, misfolded transthyretin, Neurimmune AG, NI006, rare disease, transthyretin amyloid cardiomyopathy
(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its rare diseases arm Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences, Inc., a Clinical Stage … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abnormal antibody, acquisition, AL amyloidosis, Alexion, amyloids, AstraZeneca, bone marrow, CAEL-101, Caelum Biosciences, Cardiac Amyloid Reaching for Extended Survival, CARES Phase III clinical programme, defective plasma cells, IIIb disease, immunoglobulin, light chain (AL) amyloidosis, mAb, Marc Dunoyer, Mayo stage IIIa, monoclonal antibody, rare disease
Clinical and real-world insights on recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) and the management of chronic hypoparathyroidism to be presented Hypoparathyroidism is a rare endocrine disease that can have a significant impact on patients New data highlight Shire’s commitment to … Read the full press release
LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies. The … Read the full press release
Posted in Government, Healthcare, News, Non Profit, Pharma & Biotech, Science, Society, United Kingdom
Tagged academia, Aetna, analytica|LASER, auto-immune diseases, biopharmaceutical, biopharmaceutical developers, Cancer, deadly HIV epidemic, Dr. Harold Paz, Dr. Olivier Brandicourt, Dr. Sarah Garner, drug developers, drug policy, EURORDIS-Rare Diseases Europe, French HAS, global health systems sustainability, government, health ministries, health systems, Healthcare, high-cost medical therapies, high-value medicines, Julia Corner, life-saving drugs, London School of Hygiene and Tropical Medicine, medicine access, medicine accessibility, National Institute for Health and Care Excellence, not-for-profit event, patient access, patient organisations, Pharmaceutical, Prof Peter Piot, Prof. Dominique Le Guludec, Prof. Lucien Abenhaim, rare disease, rare diseases, Renaissance St Pancras Hotel, Sanofi, Sir Andrew Dillon, Ulrich Neumann, World Health Organization, Yann Le Cam
BRUSSELS, 24-11-2015 — /EuropaWire/ — EURORDIS will be the voice of people living with a rare disease across Europe in the new INNOVCare project. INNOVCare (Innovative Patient-Centred Approach for Social Care Provision to Complex Conditions) addresses the social challenges faced … Read the full press release
Posted in Belgium, European Union, Healthcare, Society
Tagged EURORDIS, INNOVCare project, rare disease
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
